DOP41 Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.